IN2014DN08867A - - Google Patents

Info

Publication number: IN2014DN08867A
Authority: IN; India
Prior art keywords: present; quinolin; thiophen; piperazin; dihydrate
Prior art date: 2012-04-23

Application number

Other languages

English (en)

Inventor

Hiroshi Yamashita

Tetsuya Sato

Takuya Minowa

Yusuke Hoshika

Hidekazu Toyofuku

Tatsuya Yamaguchi

Masahiro Sota

Shuuji Kawano

Takayuki Nakamura

Ryohei Eto

Takuma Ikebuchi

Kei Moriyama

Nobuaki Ito

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-23

Filing date

2013-04-23

Publication date

2015-05-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN08867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-23 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2015-05-22 Publication of IN2014DN08867A publication Critical patent/IN2014DN08867A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

IN8867DEN2014 2012-04-23 2013-04-23 IN2014DN08867A (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261636920P	2012-04-23	2012-04-23
US201361791378P	2013-03-15	2013-03-15
PCT/JP2013/062681 WO2013162046A1 (en)	2012-04-23	2013-04-23	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Publications (1)

Publication Number	Publication Date
IN2014DN08867A true IN2014DN08867A (da)	2015-05-22

Family

ID=48428584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN8867DEN2014 IN2014DN08867A (da)	2012-04-23	2013-04-23

Country Status (37)

Country	Link
US (5)	US9499525B2 (da)
EP (1)	EP2841431B2 (da)
JP (1)	JP5952917B2 (da)
KR (1)	KR102160395B1 (da)
CN (1)	CN104254530B (da)
AR (1)	AR090774A1 (da)
AU (1)	AU2013253372B2 (da)
BR (1)	BR112014026424B1 (da)
CA (1)	CA2870000C (da)
CO (1)	CO7111315A2 (da)
CY (1)	CY1119103T1 (da)
DK (1)	DK2841431T4 (da)
EA (1)	EA026541B1 (da)
ES (1)	ES2617881T5 (da)
FI (1)	FI2841431T4 (da)
HK (1)	HK1203073A1 (da)
HR (1)	HRP20170242T4 (da)
HU (1)	HUE031997T2 (da)
IL (1)	IL235044B (da)
IN (1)	IN2014DN08867A (da)
JO (1)	JO3325B1 (da)
LT (1)	LT2841431T (da)
ME (1)	ME02619B (da)
MX (1)	MX361723B (da)
MY (1)	MY170220A (da)
NZ (1)	NZ630260A (da)
PH (1)	PH12014502324A1 (da)
PL (1)	PL2841431T5 (da)
PT (1)	PT2841431T (da)
RS (1)	RS55742B2 (da)
SG (1)	SG11201406790VA (da)
SI (1)	SI2841431T2 (da)
SM (1)	SMT201700130B (da)
TW (1)	TWI562991B (da)
UA (1)	UA117456C2 (da)
WO (1)	WO2013162046A1 (da)
ZA (1)	ZA201407477B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI320783B (en) *	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
TWI562991B (en) *	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
JOP20210047A1 (ar) *	2012-10-25	2017-06-16	Otsuka Pharma Co Ltd	عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
BR112016024510A2 (pt)	2014-04-22	2017-08-15	H Lundbeck As	?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
CN104447723A (zh) *	2014-11-28	2015-03-25	瑞阳制药有限公司	7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) *	2015-05-19	2015-08-12	杭州新博思生物医药有限公司	A晶型依匹唑派盐酸盐及其制备方法
CN106883223B (zh) *	2015-12-16	2021-11-23	北京福元医药股份有限公司	一种Brexpiprazole盐酸盐的纯化方法
WO2017106641A1 (en)	2015-12-17	2017-06-22	Assia Chemical Industries Ltd.	Solid state forms of brexpiprazole
JP2019059672A (ja) *	2015-12-28	2019-04-18	大日本住友製薬株式会社	治療抵抗性うつ病等の治療薬
WO2017115287A1 (en)	2015-12-28	2017-07-06	Honour (R&D)	Process for the preparation of quinoline-2(1h)-one derivatives
EP3411370A1 (en)	2016-02-01	2018-12-12	Hexal AG	Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en)	2016-05-03	2017-11-09	Cadila Healthcare Limited	Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh)	2016-05-12	2017-11-21	上海奥博生物医药技术有限公司	一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) *	2016-05-31	2017-12-07	Cipla Limited	A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (zh) *	2016-07-04	2016-12-07	山东川成医药股份有限公司	一种依匹唑派的精制方法
PL233778B1 (pl)	2016-07-19	2019-11-29	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
EP3500249A1 (en)	2016-08-16	2019-06-26	Hexal Aktiengesellschaft	Pharmaceutical compositions of a benzothiophene compound
EP3500247B1 (en)	2016-08-16	2020-05-27	H e x a l Aktiengesellschaft	Immediate release tablet of a benzothiophene compound
CN107936005A (zh) *	2016-10-13	2018-04-20	上海科胜药物研发有限公司	一种依匹哌唑新晶型ii及其制备方法
CN106699745A (zh) *	2016-12-14	2017-05-24	上海博志研新药物技术有限公司	一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
WO2018141886A1 (en)	2017-02-02	2018-08-09	Hexal Aktiengesellschaft	Crystalline brexpiprazole
EP3501506B1 (en)	2017-12-19	2019-10-09	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (zh) *	2020-03-24	2020-07-24	石药集团中奇制药技术（石家庄）有限公司	一种盐酸依匹哌唑新晶型及其制备方法
US11229644B1 (en) *	2020-12-31	2022-01-25	Lake O'hara Llc	Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) *	2021-02-16	2022-08-25	大塚製薬株式会社	非晶質体及び当該非晶質体を含む組成物
WO2023067664A1 (ja) *	2021-10-18	2023-04-27	大塚製薬株式会社	ベンゾチオフェン化合物の新規結晶形及びその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR033485A1 (es) *	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE602004017342D1 (de)	2003-10-23	2008-12-04	Otsuka Pharma Co Ltd	Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
WO2006030446A1 (en)	2004-09-13	2006-03-23	Matrix Laboratories Ltd	Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
JP4315393B2 (ja) *	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物
TWI320783B (en) *	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
AR066677A1 (es) *	2007-05-24	2009-09-02	Novartis Ag	Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
US20100285476A1 (en) *	2007-10-26	2010-11-11	Rusche James R	Methods of identifying histone deacetylase inhibitors useful for neurological disorders
AU2009209594A1 (en) *	2008-01-30	2009-08-06	Novartis Ag	Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
MX344235B (es)	2010-08-24	2016-12-07	Otsuka Pharmaceutical Co Ltd *	Suspension y composicion en torta que contiene un derivado de carbostirilo y aceite de silicona y/o un derivado de aceite de silicona.
JP2012232958A (ja) *	2011-05-09	2012-11-29	Otsuka Pharmaceut Co Ltd	注射製剤
RU2601420C2 (ru) *	2011-07-28	2016-11-10	Оцука Фармасьютикал Ко., Лтд.	СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ БЕНЗО[b]ТИОФЕНА
JO3227B1 (ar) *	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) *	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
TWI562991B (en) *	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable

2013
- 2013-04-19 TW TW102114005A patent/TWI562991B/zh active
- 2013-04-22 AR ARP130101319A patent/AR090774A1/es unknown
- 2013-04-23 FI FIEP13722129.7T patent/FI2841431T4/fi active
- 2013-04-23 CA CA2870000A patent/CA2870000C/en active Active
- 2013-04-23 PT PT137221297T patent/PT2841431T/pt unknown
- 2013-04-23 RS RS20170214A patent/RS55742B2/sr unknown
- 2013-04-23 MY MYPI2014703139A patent/MY170220A/en unknown
- 2013-04-23 HR HRP20170242TT patent/HRP20170242T4/hr unknown
- 2013-04-23 UA UAA201412555A patent/UA117456C2/uk unknown
- 2013-04-23 BR BR112014026424-4A patent/BR112014026424B1/pt active IP Right Grant
- 2013-04-23 SI SI201330538T patent/SI2841431T2/sl unknown
- 2013-04-23 ES ES13722129T patent/ES2617881T5/es active Active
- 2013-04-23 US US14/396,224 patent/US9499525B2/en active Active
- 2013-04-23 ME MEP-2017-56A patent/ME02619B/me unknown
- 2013-04-23 SG SG11201406790VA patent/SG11201406790VA/en unknown
- 2013-04-23 DK DK13722129.7T patent/DK2841431T4/da active
- 2013-04-23 KR KR1020147032745A patent/KR102160395B1/ko active IP Right Grant
- 2013-04-23 EA EA201491933A patent/EA026541B1/ru not_active IP Right Cessation
- 2013-04-23 JP JP2014550214A patent/JP5952917B2/ja active Active
- 2013-04-23 NZ NZ630260A patent/NZ630260A/en unknown
- 2013-04-23 HU HUE13722129A patent/HUE031997T2/en unknown
- 2013-04-23 JO JOP/2013/0114A patent/JO3325B1/ar active
- 2013-04-23 CN CN201380021622.6A patent/CN104254530B/zh active Active
- 2013-04-23 LT LTEP13722129.7T patent/LT2841431T/lt unknown
- 2013-04-23 IN IN8867DEN2014 patent/IN2014DN08867A/en unknown
- 2013-04-23 WO PCT/JP2013/062681 patent/WO2013162046A1/en active Application Filing
- 2013-04-23 AU AU2013253372A patent/AU2013253372B2/en active Active
- 2013-04-23 PL PL13722129.7T patent/PL2841431T5/pl unknown
- 2013-04-23 MX MX2014012527A patent/MX361723B/es active IP Right Grant
- 2013-04-23 EP EP13722129.7A patent/EP2841431B2/en active Active
2014
- 2014-10-07 IL IL235044A patent/IL235044B/en active IP Right Grant
- 2014-10-14 CO CO14226629A patent/CO7111315A2/es unknown
- 2014-10-15 ZA ZA2014/07477A patent/ZA201407477B/en unknown
- 2014-10-17 PH PH12014502324A patent/PH12014502324A1/en unknown
2015
- 2015-04-13 HK HK15103588.5A patent/HK1203073A1/xx unknown
2016
- 2016-10-14 US US15/294,644 patent/US10407415B2/en active Active
2017
- 2017-02-28 SM SM201700130T patent/SMT201700130B/it unknown
- 2017-03-07 CY CY20171100293T patent/CY1119103T1/el unknown
2019
- 2019-09-09 US US16/564,972 patent/US20200140424A1/en not_active Abandoned
2020
- 2020-08-04 US US16/985,177 patent/US20210115030A1/en not_active Abandoned
2022
- 2022-02-14 US US17/651,042 patent/US20230049327A1/en active Pending

Also Published As

Publication number	Publication date
UA117456C2 (uk)	2018-08-10
JO3325B1 (ar)	2019-03-13
DK2841431T4 (da)	2024-02-12
PL2841431T5 (pl)	2024-07-15
MX2014012527A (es)	2015-03-19
US10407415B2 (en)	2019-09-10
EP2841431B1 (en)	2017-01-04
HK1203073A1 (en)	2015-10-16
EP2841431A1 (en)	2015-03-04
KR102160395B1 (ko)	2020-09-28
WO2013162046A1 (en)	2013-10-31
FI2841431T4 (fi)	2024-04-18
ZA201407477B (en)	2015-12-23
US20230049327A1 (en)	2023-02-16
US9499525B2 (en)	2016-11-22
PL2841431T3 (pl)	2017-06-30
CY1119103T1 (el)	2018-02-14
AR090774A1 (es)	2014-12-03
CA2870000C (en)	2021-02-16
ME02619B (me)	2017-06-20
CO7111315A2 (es)	2014-11-10
PT2841431T (pt)	2017-03-07
RS55742B2 (sr)	2024-04-30
TWI562991B (en)	2016-12-21
TW201348229A (zh)	2013-12-01
HRP20170242T1 (hr)	2017-04-07
EA026541B1 (ru)	2017-04-28
JP5952917B2 (ja)	2016-07-13
DK2841431T3 (da)	2017-03-06
US20170066752A1 (en)	2017-03-09
CN104254530B (zh)	2016-09-21
BR112014026424B1 (pt)	2022-09-13
RS55742B1 (sr)	2017-07-31
PH12014502324B1 (en)	2015-01-12
ES2617881T3 (es)	2017-06-20
SI2841431T1 (sl)	2017-03-31
CA2870000A1 (en)	2013-10-31
MX361723B (es)	2018-12-14
MY170220A (en)	2019-07-10
CN104254530A (zh)	2014-12-31
US20200140424A1 (en)	2020-05-07
JP2015514677A (ja)	2015-05-21
NZ630260A (en)	2015-09-25
HRP20170242T4 (hr)	2024-03-01
US20150087655A1 (en)	2015-03-26
IL235044A0 (en)	2014-12-31
IL235044B (en)	2019-05-30
EP2841431B2 (en)	2024-01-24
SMT201700130B (it)	2017-03-08
EA201491933A1 (ru)	2015-03-31
SG11201406790VA (en)	2014-11-27
US20210115030A1 (en)	2021-04-22
BR112014026424A2 (pt)	2017-06-27
KR20150013189A (ko)	2015-02-04
AU2013253372B2 (en)	2016-12-08
HRP20170242T8 (hr)	2017-09-22
SI2841431T2 (sl)	2024-03-29
HUE031997T2 (en)	2017-08-28
ES2617881T5 (es)	2024-05-22
AU2013253372A1 (en)	2014-10-30
LT2841431T (lt)	2017-03-27
PH12014502324A1 (en)	2015-01-12

Publication	Publication Date	Title
IN2014DN08867A (da)	2015-05-22
IN2015DN01156A (da)	2015-06-26
TN2014000138A1 (en)	2015-09-30	Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015501363B1 (en)	2016-02-01	Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
PH12014502496B1 (en)	2015-01-12	Bicyclically substituted uracils and the use thereof
MY180751A (en)	2020-12-08	3,4-dihydroisoquinolin-2(1h)-yl compounds
MX2016000794A (es)	2016-12-02	Composiciones farmaceuticas de pancreatina de potencia alta.
NZ749557A (en)	2020-01-31	3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
TN2015000120A1 (en)	2016-06-29	Oxazolidin-2-one-pyrimidine derivatives
CA2929436C (en)	2021-06-15	Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2016000480A (es)	2016-10-21	Composiciones farmaceuticas de pancreatina de alta potencia.
SG10201900954SA (en)	2019-02-27	Heterocycles as Modulators of Kinase Activity
TN2014000532A1 (en)	2016-03-30	N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
MX2014007364A (es)	2014-08-01	Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
PH12015500322B1 (en)	2015-03-30	Tris(hetero)arylpyrazoles and use thereof
IN2014DN10683A (da)	2015-08-28
MX2013002446A (es)	2013-04-08	Derivados de tetrahidropirrolopirazina sustituidos.
TN2014000085A1 (en)	2015-07-01	Substituted annellated pyrimidine and the use thereof
IN2013MU03838A (da)	2015-07-31